Aligos Therapeutics, Inc.
ALGS
$7.34
$0.395.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -77.19% | -23.21% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -77.19% | -23.21% | |||
| Cost of Revenue | -28.82% | 71.27% | |||
| Gross Profit | 27.28% | -78.28% | |||
| SG&A Expenses | -4.26% | -7.04% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -24.46% | 49.00% | |||
| Operating Income | 23.08% | -52.75% | |||
| Income Before Tax | 36.94% | -100.80% | |||
| Income Tax Expenses | -46.43% | -69.73% | |||
| Earnings from Continuing Operations | 36.96% | -98.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 36.96% | -98.81% | |||
| EBIT | 23.08% | -52.75% | |||
| EBITDA | 23.40% | -53.71% | |||
| EPS Basic | 37.05% | -98.45% | |||
| Normalized Basic EPS | 37.03% | -100.44% | |||
| EPS Diluted | 36.96% | -98.45% | |||
| Normalized Diluted EPS | 37.03% | -100.44% | |||
| Average Basic Shares Outstanding | 0.14% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.14% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||